FY2025 EPS Estimates for Arcellx Cut by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised Arcellx's FY2025 earnings per share estimate down to ($3.72), from a previous estimate of ($2.98), maintaining a "Hold" rating with an $88.00 price objective.
• Despite a downgrading of earnings estimates, analysts have mixed opinions on the stock, with various ratings ranging from "Strong Buy" to "Sell," alongside an average target price of $112.69.
• Arcellx's stock experienced a 1.8% decline recently, with the current price around $86.80, amidst ongoing trading and investment activity from institutional investors.

Arcellx, Inc. (NASDAQ:ACLX - Free Report) - Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for shares of Arcellx in a research report issued on Thursday, October 9th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings per share of ($3.72) for the year, down from their prior forecast of ($2.98). Cantor Fitzgerald has a "Hold" rating and a $88.00 price objective on the stock. The consensus estimate for Arcellx's current full-year earnings is ($1.58) per share. Cantor Fitzgerald also issued estimates for Arcellx's FY2026 earnings at ($3.56) EPS.

Other analysts have also issued research reports about the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Arcellx in a report on Wednesday, October 8th. Citigroup assumed coverage on Arcellx in a report on Tuesday, June 17th. They set a "buy" rating and a $110.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $115.00 price objective on shares of Arcellx in a report on Monday, June 16th. Finally, Scotiabank lifted their price objective on Arcellx from $93.00 to $133.00 and gave the stock a "sector outperform" rating in a report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $112.69.

Arcellx Stock Down 1.8%

ACLX opened at $86.80 on Monday. Arcellx has a 12-month low of $47.86 and a 12-month high of $107.37. The firm has a market capitalization of $4.81 billion, a P/E ratio of -25.38 and a beta of 0.31. The stock's 50 day moving average price is $75.42 and its two-hundred day moving average price is $68.00.

Arcellx (NASDAQ:ACLX - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.03) by $0.09. The firm had revenue of $7.55 million for the quarter, compared to analyst estimates of $16.76 million. Arcellx had a negative return on equity of 43.04% and a negative net margin of 329.93%.

Hedge Funds Weigh In On Arcellx

Hedge funds and other institutional investors have recently modified their holdings of the stock. State of Wyoming bought a new position in shares of Arcellx during the 2nd quarter worth approximately $28,000. GAMMA Investing LLC raised its position in Arcellx by 104.1% in the 1st quarter. GAMMA Investing LLC now owns 494 shares of the company's stock valued at $32,000 after purchasing an additional 252 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Arcellx by 183.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 751 shares of the company's stock valued at $49,000 after purchasing an additional 486 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in Arcellx in the 1st quarter valued at $50,000. Finally, GF Fund Management CO. LTD. raised its position in Arcellx by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,384 shares of the company's stock valued at $91,000 after purchasing an additional 249 shares during the last quarter. Institutional investors own 96.03% of the company's stock.

Insider Activity at Arcellx

In related news, insider Christopher Heery sold 21,034 shares of the firm's stock in a transaction that occurred on Tuesday, September 30th. The stock was sold at an average price of $81.28, for a total transaction of $1,709,643.52. Following the completion of the transaction, the insider owned 624 shares in the company, valued at $50,718.72. This trade represents a 97.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 37,146 shares of company stock worth $3,000,136. 8.35% of the stock is owned by company insiders.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.